Phosphogliv, lyophilizate. 500 mg+200 mg 2.5g 5 pcs

Combined remedy.

It has membrane stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the main component of phospholipids) is the main structural element of cell and intracellular membranes and can restore their structure and functions in case of damage, providing a cytoprotective effect.

Normalizes protein and lipid metabolism, prevents loss of enzymes and other active substances by hepatocytes, restores liver function, inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.

Glycyrrhizic acid has anti-inflammatory effects, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis and increasing the activity of natural killer cells.

It has hepatoprotective effect due to antioxidant and membrane stabilizing activity. Glycyrrhizic acid potentiates the effect of endogenous glucocorticosteroids with anti-inflammatory and anti-allergic effect in non-infectious liver lesions.

In skin lesions due to the membrane stabilizing and anti-inflammatory action of the components limits the spread of the process and promotes the regression of the disease.

Pharmacokinetics.

Phosphatidylcholine
Binding primarily to high-density lipoproteins, phosphatidylcholine is delivered, particularly to liver cells. Half-life of the choline component is 66 hours, and of unsaturated fatty acids – 32 hours.
Glycyrrhizic acid
Glycyrrhizic acid, entering the systemic bloodstream, is bound to albumin and transported to the liver. Glycyrrhizic acid is excreted with bile in unchanged form, in residual amount – with urine. On entering the intestine some of it is hydrolyzed under the action of β-glucuronidase of the intestinal microflora into β-glycyrrhetic acid which is reabsorbed causing enterohepatic circulation.
An experimental data, the inclusion of glycyrrhizic acid in phospholipid nanoparticles improves its pharmacokinetic and pharmacodynamic properties, prolongs the circulation in the blood and increases the entry into the liver.

In addition, the inclusion of glycyrrhizic acid in phospholipid nanoparticles contributes to improving its pharmacokinetic and pharmacodynamic properties.

Indications

Poisoning, Jaundice, Hepatitis, Neurodermatitis, Psoriasis, Alcoholism, Weakness and fatigue, Nausea, Eczema, After a course of antibiotic therapy, liver damage

• fatty liver degeneration (hepatosis), alcohol, toxic, including drugs, liver damage.
• In the complex treatment of viral hepatitis (acute and chronic), cirrhosis and psoriasis.
  

Active ingredient

Glycyrrhizic acid, Phospholipids

Composition

1 vial contains:

Active ingredients:

Phospholipids (Lipoid C 100) – 0.50 g

Trisodium salt of glycyrrhizic acid (sodium glycyrrhizinate) – 0.20 g

Ancillary substance:

Maltose – 1.80 g